Cargando…
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for...
Autores principales: | McCreary, Erin K, Pogue, Jason M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144823/ https://www.ncbi.nlm.nih.gov/pubmed/32284951 http://dx.doi.org/10.1093/ofid/ofaa105 |
Ejemplares similares
-
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
por: Davis, Matthew R., et al.
Publicado: (2020) -
Monoclonals for patients hospitalised with COVID-19
por: Pogue, Jason M, et al.
Publicado: (2022) -
Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment
por: Woltemate, Thomas J., et al.
Publicado: (2021) -
2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR) Pseudomonas aeruginosa
por: Shah, Sunish, et al.
Publicado: (2023) -
Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)
por: McCreary, Marvin R., et al.
Publicado: (2021)